natgillin/translations-raw huggingface dataset:
A bone disease called osteochondrosis
bolezen kosti, ki se imenuje osteohondroza
A booster (fourth) dose is recommended at least 6 months after the last priming dose and preferably between 12 and 15 months of age (see sections 4.4 and 5.1).
Obnovitveni (četrti) odmerek je priporočljivo dati vsaj 6 mesecev po zadnjem odmerku primarnega cepljenja in po možnosti med 12. in 15. mesecem starosti (glejte poglavji 4.4 in 5.1).
A booster (third) dose is recommended at least 6 months after the last primary dose (see section 5.1).
Obnovitveni (tretji) odmerek je priporočljiv vsaj 6 mesecev po zadnjem primarnem odmerku (glejte poglavje 5.1).
A booster dose (third dose) should be given within the second year (i.e.
Dodatni odmerek (tretji) je treba dati drugo leto (tj.
A booster dose (third dose) should be given within the second year (i.e.
Obnovitveni (tretji) odmerek je treba dati v drugem letu (tj.
A booster dose of Infanrix hexa or a similar vaccine must be given at least six months after the last dose of the initial course.
Obnovitveni odmerek cepiva Infanrix hexa ali podobnega cepiva je treba dati najmanj šest mesecev po zadnjem odmerku začetnega cepljenja.
A booster dose of Menveo was administered 5 years after primary vaccination with Menveo or ACWY-PS.
Poživitveni odmerek cepiva Menveo so aplicirali 5 let po osnovnem cepljenju s cepivom Menveo ali ACWY-PS.
A booster vaccination with a 7.5 µg heterologous A/Indonesia/05/2005 vaccine strain has been administered in a time window of 12 to 24 months after priming vaccination with two doses of the A/Vietnam/1203/2004 strain vaccine in three clinical studies in adults aged 18 to 59 years and in older aged 60 years and above.
V treh kliničnih študijah pri odraslih, starih od 18 do 59 let, in starejših osebah, starih 60 let in več, so opravili poživitveno cepljenje s 7,5 µg heterolognega cepilnega seva A/Indonesia/05/2005 v časovnem oknu od 12 do 24 mesecev po primarnem cepljenju z dvema odmerkoma cepiva s sevom A/Vietnam/1203/2004.
A booster vaccination with a 7.5 µg heterologous A/Indonesia/05/2005 vaccine strain has been administered in a time window of 12 to 24 months after priming vaccination with two doses of the A/Vietnam/1203/2004 strain vaccine in three clinical studies in adults aged 18 to 59 years and in older people aged 60 years and above.
V treh kliničnih študijah pri odraslih, starih od 18 do 59 let, in starejših osebah, starih 60 let in več, so opravili poživitveno cepljenje s 7,5 µg heterolognega cepilnega seva A/Indonesia/05/2005 v časovnem oknu od 12 do 24 mesecev po primarnem cepljenju z dvema odmerkoma cepiva s sevom A/Vietnam/1203/2004.
A bottle adapter and 2 oral dispensers are also provided.
Dodana sta tudi nastavek za steklenico in 2 peroralna razdelilnika.
A bottle of prepared Tamiflu oral suspension
teklenico s pripravljeno peroralno suspenzijo zdravila Tamiflu
A bottle of prepared Tamiflu oral suspension
teklenico s pripravljeno peroralno suspenzijo zdravila Tamiflu,
A break in treatment or a decrease in dose may be required when lipase is increased. liver tests
Pri zvišanju lipaze bo morda treba zdravljenje prekiniti ali zmanjšati odmerek. opravil jetrne teste
A brief period of hypersalivation (drooling) may occur if the animal licks the application site immediately after treatment.
Če žival liže mesto nanosa, je mogoče takoj po nanosu opaziti kratko obdobje hipersalivacije (prekomerno slinjenje).
A broken or crushed tablet may taste bad and there is a possibility that you will receive an incorrect dose.
Prelomljena ali zdrobljena tableta je lahko neprijetnega okusa in obstaja možnost, da ne boste prejeli pravega odmerka.
A build-up of phosphate leads to hyperphosphataemia and in the long-term can cause complications such as heart and bone disease.
Kopičenje fosfatov povzroča hiperfosfatemijo, ki lahko dolgoročno vodi do zapletov, kot so bolezni srca in kosti.
a burning sensation
pekoč občutek.
a Calculated as (C30min-baseline factor IX) divided by the dose in IU/kg, where C30min is the factor IX measurement 30 minutes after infusion.
a Izračunano kot (C30 min – izhodiščni faktor IX), deljeno z odmerkom v i.e./kg, pri čemer je C30 min vrednost meritve faktorja IX 30 minut po infuziji.
a Calculated as (C30min-baseline factor IX) divided by the dose in IU/kg, where C30min is the factor IX measurement 30 minutes after infusion. b If not coinciding with week 26 visit.
a Izračunano kot (C30 min – izhodiščni faktor IX), deljeno z odmerkom v i.e./kg, pri čemer je C30 min vrednost meritve faktorja IX 30 minut po infuziji. b Če se ne ujema s 26. tednom.
a Calculated as (Cmax - baseline Factor VIII) divided by the dose in IU/kg, where Cmax is the maximal post- infusion Factor VIII measurement.
a) Izračunano kot (Cmax – osnovna vrednost faktorja VIII), deljeno z odmerkom v i.e./kg, kjer je Cmax najvišja izmerjena vrednost faktorja VIII po infuziji.
a Calculated as (Cmax - baseline Factor VIII) divided by the dose in IU/kg, where Cmax is the maximal post-infusion Factor VIII measurement.
a) Izračunano kot (Cmax – osnovna vrednost faktorja VIII), deljeno z odmerkom v i.e./kg, kjer je Cmax najvišja izmerjena vrednost faktorja VIII po infuziji.
a Calculated from data of 18 breast cancer patients who received four peritumoural injections of 4, 20, and 100 microgram doses of Lymphoseek. b Blood represents total body exposure segregated from independent measurements of other organs and tissues.
a Izračunano na podlagi podatkov 18 bolnic z rakom dojke, ki so prejele štiri peritumorna injiciranja odmerkov zdravila Lymphoseek 4, 20 in 100 mikrogramov. b Kri predstavlja izpostavljenost celotnega telesa, ločenega od posameznih meritev za druge organe in tkiva.
a Calculated from data of 18 melanoma patients who received four intradermal injections of 20, 100, and 200 microgram doses of Lymphoseek. b Blood represents total body exposure segregated from independent measurements of other organs and tissues.
a Izračunano na podlagi podatkov 18 bolnikov z melanomom, ki so prejeli štiri intradermalna injiciranja odmerkov zdravila Lymphoseek 20, 100 in 200 mikrogramov. b Kri predstavlja izpostavljenost celotnega telesa, ločenega od posameznih meritev za druge organe in tkiva.
a calculated using the Schwartz formula b dose is based on CrCL.
a Izračunano z uporabo Schwartzove formule. b Odmerek temelji na očistku kreatinina.
A calendar card is provided in the pack, numbered 1-31 for each day of the month.
V paketu je priložena koledarska kartica s številkami 1–31 za vsak dan v mesecu.
A calibrated quantitative (dTT) test or repetitive dTT measurements allow prediction of the time by when certain dabigatran levels will be reached (see section 5.1), also in case additional measures e.g. dialysis have been initiated.
S kalibriranim kvantitativnim testom dTT ali ponovljenimi meritvami dTT lahko napovemo čas, v katerem bo dosežena določena raven dabigatrana (glejte poglavje 5.1), tudi po uvajanju dodatnih ukrepov, na primer dialize.
A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalized ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) – see SmPC.
Uporaba kalibriranega kvantitativnega testa aktivnosti anti-FXa je lahko koristna v izjemnih okoliščinah, npr. v primeru prevelikega odmerjanja ali nujnega kirurškega posega (PČ, INR in aPTČ testi strjevanja krvi niso primerni) – glejte povzetek glavnih značilnosti zdravila.
A calibrating measuring spoon is provided.
Priložena je umerjena odmerna žlička.
a cancer of the bone marrow (multiple myeloma);
rak kostnega mozga (multipli mielom),
A carcinogenicity study with buprenorphine/naloxone was conducted in rats at doses of 7, 30 and
Študijo karcinogenosti z buprenorfinom/naloksonom so izvedli pri podganah v odmerkih 7, 30 in
a card
(PVC/alu) v
A careful benefit/risk assessment should be made, taking into consideration that the liver toxicity is dose dependent (see sections 4.4 and 5.1).
Skrbno moramo oceniti razmerje med koristjo in tveganjem, pri čemer upoštevamo, da odmerek vpliva na toksičnost za jetra (glejte poglavji 4.4 in 5.1).
A careful benefit/risk assessment should be made, taking into consideration the liver toxicity of bosentan (see sections 4.4 and 4.8).
Skrbno moramo oceniti razmerje med koristjo in tveganjem, pri čemer upoštevamo, toksičen vpliv bosentana za jetra (glejte poglavji 4.4 in 4.8).
A central analysis of ECG data demonstrated new QTc >500 msec in one patient (0.2%).
Glede na centralno analizo EKG podatkov je do podaljšanja intervala QTc na >500 ms na novo prišlo pri enem bolniku (0,2 %).
A certain number of adverse reactions, generally attributed to interferon therapy but that have been reported in the context of hepatitis C therapy (in combination with ribavirin) are also listed for reference in Table 4.
V Preglednici 4 je za primerjavo podano tudi nekaj neželenih učinkov, ki so jih običajno pripisovali zdravljenju z interferonom, vendar so jih prijavili tudi med zdravljenjem hepatitisa C (v kombinaciji z ribavirinom).
A certain type of allergic reaction called serum sickness has been observed in patients treated with Xolair.
Pri bolnikih, ki so prejemali zdravilo Xolair, so opažali določeno vrsto alergijske reakcije, ki se imenuje serumska bolezen.
a certain type of cancer of the head and neck (squamous cell cancer).
Določenega tipa raka glave in vratu (raka skvamoznih celic).
a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50%
odprtjem materničnega vratu od 1 do 3 cm (od 0 do 3 cm pri ženskah, ki še niso rodile) in stanjšanjem za ≥ 50 %;
a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of  50%
odprtjem materničnega vratu od 1 do 3 cm (od 0 do 3 cm pri ženskah, ki še niso rodile) in stanjšanjem za  50 %;
A change in dose should only be based on a consistent change in the patient’s body weight over time.
Sprememba odmerka mora temeljiti na spremembi bolnikove telesne mase.
a change in how you walk, speech problems
prememba hoje, težave z govorom;
a change in how your body regulates fluids within your body and may result in puffiness
prememba načina, kako telo uravnava tekočine v telesu, kar lahko povzroči nabreklost
a change in how your body regulates fluids within your body and may result in puffiness
premenjen način telesnega reguliranja tekočin v telesu, ki lahko povzroči zabuhlost
a change in how your body regulates fluids within your body and may result in puffiness
premenjeno telesno uravnavanje tekočin, ki lahko povzroči oteklost
a change in the salt level in your blood shown in blood tests - signs include feeling confused or weak
prememba koncentracije soli v krvi, ki se pokaže na preiskavah krvi – med znaki sta občutek zmedenosti ali šibkost
a change in the salt level in your blood shown in blood tests signs include feeling confused or weak
prememba koncentracije soli v krvi, ki se pokaže na preiskavah krvi – med znaki sta občutek zmedenosti ali šibkost
a change in the way things taste or the complete loss of taste,
premenjeno okušanje ali popolna izguba okusa,
a change in the way you walk
prememba načina hoje
a change in the way you walk
prememba v načinu hoje
a change in your sense of smell
prememba voha
A change of 5 points in the TOI-B is considered clinically significant.
Sprememba za 5 točk na TOI-B velja za klinično pomembno.
A child-resistant cap, which must be put on the nasal spray, when the nasal spray is not used
za otroke varno zaporko, ki jo je treba namestiti, ko se pršilo za nos ne uporablja;
A cilostazol dosage of 50 mg twice daily is recommended in combination with Ketoconazole HRA.
V kombinaciji z zdravilom Ketokonazol HRA se priporoča odmerek cilostazola 50 mg dvakrat na dan.
A clean pair of scissors is used to cut each sachet along the dotted line.
Vsako vrečico prerežite vzdolž črtkane linije s čistimi škarjami.
a cleansing swab
dezinfekcijska krpica,
A clear or slightly pearl-like solution should be obtained, usually in about 1 minute (5 minutes maximum).
Raztopina, ki jo dobite po eni minuti (ali največ po 5 minutah), mora biti bistra ali rahlo bisernata.
A clear or slightly pearl-like solution should be obtained, usually in less than 1 minute (5 minutes maximum).
Raztopina, ki jo dobite običajno po manj kot eni minuti (ali največ po 5 minutah), mora biti bistra ali rahlo bisernata.
A clear to slightly opalescent and colourless to pale yellow solution.
Bistra do rahlo opalescentna in brezbarvna do bledo rumena raztopina.
A clear to slightly opalescent, and colourless to pale yellow solution.
Raztopina je bistra do rahlo opalescentna, brezbarvna do bledo rumene barve.
A clear, colourless to slightly yellow concentrate with pH 7.0 - 7.4.
Bister, brezbarven do rahlo rumen koncentrat s pH 7,0 - 7,4.
A clear, colourless to yellow or brown-coloured solution
Bistra brezbarvna do rumena ali rjava raztopina
A clear, colourless to yellow solution.
Bistra brezbarvna do rumena raztopina
A clear, greenish yellow solution.
Prozorna, zelenkasto rumena raztopina.
A clear, yellow to amber solution
Bistra, rumena do jantarna raztopina
A clear, yellow to amber solution
Bistra, rumena do jantarna raztopina.
A clicking sound can be heard, which will stop when the injection button has been pressed in completely.
Slišali boste klikajoč zvok, ki se bo končal, ko bo gumb za injiciranje do konca pritisnjen.
A clicking sound can be heard, which will stop when the injection button has been pressed in completely.
Slišali boste klikanje, ki se bo končalo, ko bo gumb za injiciranje pritisnjen do konca.
A clicking sound can be heard, which will stop when the injection button has been pressed in completely.
Sliši se klikajoč zvok, ki se konča, ko je gumb za injiciranje pritisnjen do konca.
A clinical interaction study performed in healthy subjects showed that co-administration of repeat-dose anagrelide 1 mg once daily and acetylsalicylic acid 75 mg once daily may enhance the anti-platelet aggregation effects of each active substance compared with administration of acetylsalicylic acid alone.
Študija kliničnega medsebojnega delovanja, opravljena pri zdravih osebah, je pokazala, da lahko sočasno dajanje ponavljajočih se enomiligramskih odmerkov anagrelida in acetilsalicilne kisline v odmerku 75 mg enkrat na dan zveča antiagregacijske učinke posamezne zdravilne učinkovine v primerjavi z dajanjem samo acetilsalicilne kisline.
A clinical probe substrate study was performed to evaluate the effect of 14 days of dosing with 160 mg regorafenib on the pharmacokinetics of probe substrates of CYP2C8 (rosiglitazone) CYP2C9
Izvedena je bila klinična študija preskušanja substrata za oceno učinka 14-dnevne uporabe 160 mg regorafeniba na farmakokinetiko preskušanih substratov CYP2C8 (rosiglitazon), CYP2C9
A clinical QTc study with telavancin doses of 7.5 and 15 mg/kg versus vehicle and an active comparator (400 mg moxifloxacin) showed that once daily dosing for 3 days resulted in a mean vehicle corrected increase in QTcF by 4.1 and 4.5 millisecond, respectively, compared to a
Klinična študija QTc z odmerkoma telavancina 7,5 in 15 mg/kg v primerjavi z vehiklom in aktivnem komparatorju (400 mg moksifloksacina) je pokazala, da je en dnevni odmerek za 3 dni povzročil srednje povišanje QTcF s popravkom medija za 4,1 in 4,5 milisekund v primerjavi z
A clinical response is normally seen within 3 - 4 days.
Klinični odziv na zdravljenje je običajno opazen po 3 – 4 dneh.
A clinical response is normally seen within 3 - 4 days.
Klinični odziv na zdravljenje je običajno opazen po 3–4 dneh.
A clinical response is normally seen within 3 – 4 days.
Klinični odziv na zdravljenje je običajno opazen po 3 – 4 dneh.
A clinical response is normally seen within 3-4 days.
Klinični odziv je običajno opazen v roku 3–4 dni.
A clinical response is normally seen within 3–4 days.
Klinični odziv na zdravljenje je običajno opazen po 3 do 4 dneh.
A clinical response is normally seen within a week.
Klinični odgovor je ponavadi viden v enem tednu.
A clinical study (D-H5N1-009) evaluated the reactogenicity in children 3 to 5 and 6 to 9 years of age who received either two adult (i.e.
S klinično študijo (D-H5N1-009) so ocenili reaktogenost pri otrocih, starih od 3 do 5 in od 6 do 9 let, ki so dobili v presledku 21 dni bodisi dva odmerka za odrasle (tj.
A clinical study (D-H5N1-009), evaluated the reactogenicity in children 3 to 5 and 6 to 9 years of age who received either two adult (i.e.
V klinični študiji (D-H5N1-009) so ocenili reaktogenost pri otrocih, starih od 3 do 5 in od 6 do 9 let, ki so v presledku 21 dni prejeli bodisi dva odmerka za odrasle (t.j.
A clinical study (Protocol 016) compared the immunogenicity of Gardasil in 10- to 15-year-old girls to those in 16- to 23-year old women.
Klinična študija (Protokol 016) je primerjala imunogenost cepiva Gardasil pri 10- do 15-letnih deklicah z imunogenostjo pri 16- do 23-letnih ženskah.
A clinical study in healthy volunteers has shown that fesoterodine 8 mg once daily has no significant effect on the pharmacokinetics or the anticoagulant activity of a single dose of warfarin.
Klinična študija pri zdravih prostovoljcih je pokazala, da odmerek 8 mg fesotreodina enkrat na dan nima pomembnih učinkov na farmakokinetiko ali antikoagulacijsko aktivnost enkratnega odmerka varfarina.
A clinical study in patients with moderate to severe psoriasis was designed to assess the efficacy and safety of long-term maintenance therapy versus re-treatment with an induction regimen of infliximab (maximum of four infusions at 0, 2, 6 and 14 weeks) following disease flare.
Pri bolnikih z zmerno do hudo psoriazo je bila načrtovana klinična študija za oceno učinkovitosti in varnosti dolgotrajnega vzdrževalnega zdravljenja v primerjavi s ponovno uporabo uvodne sheme zdravljenja z infliksimabom (največ štiri infuzije v 0., 2., 6. in 14. tednu) po izbruhu bolezni.
A clinical study in patients with moderate to severe psoriasis was designed to assess the efficacy and safety of long-term maintenance therapy versus re-treatment with an induction regimen of Remicade (maximum of four infusions at 0, 2, 6 and 14 weeks) following disease flare.
Pri bolnikih z zmerno do hudo psoriazo je bila načrtovana klinična študija za oceno učinkovitosti in varnosti dolgotrajnega vzdrževalnega zdravljenja v primerjavi s ponovnim dajanjem uvodne sheme zdravljenja z zdravilom Remicade (največ štiri infuzije v 0., 2., 6. in 14. tednu) po izbruhu bolezni.
A clinical study in patients with permanent AF (AF duration for at least 6 months) and cardiovascular risk factors was stopped early due to an excess of cardiovascular death, stroke and heart failure in patients receiving MULTAQ (see section 5.1).
Klinično študijo pri bolnikih s permanentno AF (trajanje AF vsaj 6 mesecev) in kardiovaskularnimi dejavniki tveganja so predčasno končali zaradi presežka kardiovaskularnih smrti, možganskih kapi in srčnega popuščanja, med bolniki, ki so prejemali zdravilo MULTAQ (glejte poglavje 5.1).
A clinical study performed in Africa (Rotarix: N = 2,974; placebo: N = 1,443) evaluated Rotarix given at approximately 10 and 14 weeks of age (2 doses) or 6, 10 and 14 weeks of age (3 doses).
Klinična študija, izvedena v Afriki (cepivo Rotarix: n = 2.974; placebo: n = 1.443), je ovrednotila cepivo Rotarix, dano v starosti približno 10 in 14 tednov (2 odmerka) ali v starosti približno 6, 10 in 14 tednov (3 odmerki).
A clinical study performed in Europe evaluated Rotarix given according to different European schedules (2, 3 months; 2, 4 months; 3, 4 months; 3, 5 months) in 4000 subjects.
Klinična študija, izvedena v Evropi, je pri približno 4.000 osebah vrednotila dajanje cepiva Rotarix po različnih shemah dajanja, ki se uporabljajo v Evropi (2. in 3. mesec; 2. in 4. mesec; 3. in 4. mesec; 3. in 5. mesec).
A clinical study performed in Latin America evaluated Rotarix in more than 20000 subjects.
Klinična študija, izvedena v Latinski Ameriki, je cepivo Rotarix ovrednotila pri več kot 20000 osebah.
A clinical study report should be submitted.
Predložiti je treba poročilo o klinični študiji.
A clinical study to evaluate the impact of itraconazole, a known CYP3A inhibitor has shown that co- administration with olaparib increased mean olaparib Cmax 1.42-fold (90% CI: 1.33-1.52) and mean AUC 2.70-fold (90% CI: 2.44-2.97).
Klinična študija za oceno vpliva itrakonazola, ki je znan zaviralec CYP3A, je pokazala, da je njegova sočasna uporaba z olaparibom povečala srednjo vrednost Cmax olapariba za 1,42-krat (90 % IZ: 1,33 do 1,52) in srednjo vrednost AUC olapariba za 2,70-krat (90 % IZ: 2,44 do 2,97).
A clinical study to evaluate the impact of rifampicin, a known CYP3A inducer has shown that co- administration with olaparib decreased olaparib mean Cmax by 71% (Treatment ratio: 0.29; 90% CI: 0.24-0.33) and mean AUC by 87% (Treatment ratio: 0.13; 90% CI: 0.11-0.16).
Klinična študija za oceno vpliva rifampicina, ki je znan induktor CYP3A, je pokazala, da je njegova sočasna uporaba z olaparibom zmanjšala srednjo vrednost Cmax olapariba za 71 % (razmerje zdravljenj: 0,29, 90 % IZ: 0,24 do 0,33) in srednjo vrednost AUC olapariba za 87 % (razmerje zdravljenj: 0,13, 90 % IZ: 0,11 do 0,16).
A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and inhibition of CYP2D6 activity in the presence of PREZISTA/ritonavir, which may be attributed to the presence of low dose ritonavir.
Klinična študija v kateri so uporabljali mešanico zdravilnih učinkovin, ki se presnavljajo s citokromi CYP2C9, CYP2C19 in CYP2D6 je v prisotnosti zdravila PREZISTA/ritonavir pokazala zvečanje aktivnosti CYP2C9 in CYP2C19 ter zmanjšanje aktivnosti CYP2D6, kar lahko pripišemo prisotnosti majhnega odmerka ritonavirja.
A clinical study was conducted with ProQuad administered with a 2-dose schedule, the doses being given 3 months apart in 1,620 healthy subjects from 9 to 12 months of age at the time of first dose.
Pri 1.620 zdravih osebah, ki so bile ob prejetju prvega odmerka stare od 9 do 12 mesecev, so izvedli klinično študijo, v kateri so s cepivom ProQuad cepili v 2 odmerkih, v razmiku 3 mesecev.
A clinical study was conducted with the quadrivalent measles, mumps, rubella and varicella vaccine manufactured by Merck & Co., Inc., administered with a 2-dose schedule, the doses being given 3 months apart in 1,620 healthy subjects from 9 to 12 months of age at the time of first dose.
Pri 1.620 zdravih osebah, ki so bile ob prejetju prvega odmerka, stare od 9 do 12 mesecev, so izvedli klinično študijo s štirivalentnim cepivom proti ošpicam, mumpsu, rdečkam in noricam izdelovalca Merck & Co., Inc., s katerim so cepili v 2 odmerkih, v razmiku 3 mesecev.
A clinical trial (Study V87P6) was conducted with a H5N1 vaccine combined with MF59C.1 adjuvant (n=334) vs seasonal influenza vaccine (n=137).
V kliničnem preskušanju (študija V87P6) so primerjali cepivo H5N1, kombinirano z adjuvansom MF59C.1 (n = 334), s sezonskim cepivom proti gripi (n = 137).
A clinical trial (Study V87P6) was conducted with a H5N1 vaccine combined with MF59C.1 adjuvant in 471 children from 6 months to 17 years of age.
MF59C.1 u 471 detí vo veku od 6 mesiacov do 17 rokov.
A clinical trial evaluated 50 CHC patients with either moderate (creatinine clearance 30 to 50 mL/min) or severe (creatinine clearance less than 30 mL/min) renal impairment, or with end stage renal disease (ESRD) requiring chronic hemodialysis (HD).
V kliničnem preskušanju so ovrednotili 50 bolnikov s kroničnim hepatitisom C, ki so imeli zmerno (kreatininski očistek 30 do 50 ml/min), hudo (kreatininski očistek manj kot 30 ml/min) ledvično okvaro ali končno ledvično odpoved, pri kateri je potrebna kronična hemodializa.